等待開盤 09-23 09:30:00 美东时间
+0.600
+0.61%
Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly
06-02 20:41